NCT05964335Phase 2Completed

Cough Reduction in IPF With Nalbuphine ER

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-04-24Actual

Enrollment · participants165Actual

Source updated2026-06-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Idiopathic Pulmonary Fibrosis

Treatments or interventions studied

NAL ERDrugAlso known as Nalbuphine
PlaceboDrug
NAL ERDrugAlso known as Nalbuphine
NAL ERDrugAlso known as Nalbuphine

Primary outcomes · main study measures

Read the study measures

measure: Relative Change From Baseline in 24-hour Cough Frequency at Week 6; description: Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.; timeFrame: Baseline, Week 6

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history